Dynavax Technologies Corporation (DVAX)
- Previous Close
12.06 - Open
11.91 - Bid 10.32 x 100
- Ask 13.64 x 100
- Day's Range
11.64 - 12.13 - 52 Week Range
10.48 - 15.15 - Volume
1,655,879 - Avg. Volume
2,122,261 - Market Cap (intraday)
1.58B - Beta (5Y Monthly) 1.19
- PE Ratio (TTM)
172.43 - EPS (TTM)
0.07 - Earnings Date Aug 1, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
25.75
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.
www.dynavax.com408
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: DVAX
Performance Overview: DVAX
Trailing total returns as of 6/10/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DVAX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DVAX
Valuation Measures
Market Cap
1.58B
Enterprise Value
1.11B
Trailing P/E
172.43
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.61
Price/Book (mrq)
2.55
Enterprise Value/Revenue
4.69
Enterprise Value/EBITDA
49.95
Financial Highlights
Profitability and Income Statement
Profit Margin
3.90%
Return on Assets (ttm)
-1.35%
Return on Equity (ttm)
1.56%
Revenue (ttm)
236.15M
Net Income Avi to Common (ttm)
9.22M
Diluted EPS (ttm)
0.07
Balance Sheet and Cash Flow
Total Cash (mrq)
723.54M
Total Debt/Equity (mrq)
41.41%
Levered Free Cash Flow (ttm)
43.91M
Research Analysis: DVAX
Company Insights: DVAX
DVAX does not have Company Insights
Research Reports: DVAX
What does Argus have to say about DVAX?
DYNAVAX TECHNOLOGIES CORP has an Investment Rating of SELL; a target price of $9.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetWhat does Argus have to say about DVAX?
DYNAVAX TECHNOLOGIES CORP has an Investment Rating of SELL; a target price of $9.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetLowering target price to $9.00
DYNAVAX TECHNOLOGIES CORP has an Investment Rating of SELL; a target price of $9.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetWhat does Argus have to say about DVAX?
DYNAVAX TECHNOLOGIES CORP has an Investment Rating of SELL; a target price of $10.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice Target